Lorazepam Challenge for Individuals at Varying Genetic Risk for Alzheimer Disease
Introduction: This study set out to clarify the differential acute cognitive impact of lorazepam based on varying genetic risk for Alzheimer disease. Methods: Fifty-seven cognitively unimpaired individuals aged 51 to 88, genotyped according to apolipoprotein E […]
Influence of amyloid and apolipoprotein E on cognitive performance in a late middle-aged cohort
Introduction: Few studies have examined the effects of amyloid and apolipoprotein E (APOE) genotype on cognition among middle-aged individuals. Methods: We included 464 cognitively normal, test-naïve, participants with Pittsburgh compound B positron emission tomography amyloid imaging, […]
A 24-week Study to Evaluate the Effect of Rilapladib on Cognition and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease
Background: The lipoprotein-associated phospholipase A2 inhibitor (Lp-PLA2), rilapladib (SB659032), is being evaluated as a potential treatment to slow the progression of Alzheimer’s disease (AD). Methods: One hundred twenty-four subjects with possible mild AD and with neuroimaging […]
Episodic memory decline predicts cortical amyloid status in community-dwelling older adults
Intra-individual decline in memory and cognition is characteristic of prodromal Alzheimer’s disease (AD) and may allow detection of very early AD pathology. Episodic memory task scores on a brief computerized cognitive battery (CogState) were prospectively evaluated […]
Use of the CogState Brief Battery in the assessment of Alzheimer’s disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study
The aim of this study was to validate the CogState Brief Battery, which assesses psychomotor, attentional, working memory, and visual learning functions, in healthy older people and in patients with mild cognitive impairment (MCI) and Alzheimer’s […]